Default company panoramic image
64aec0e1 75ee 4659 aa56 69885402d6f9

DiagNodus Limited

A colorectal cancer screening technology focused on replacing FOBT workdwide.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Cambridge, England, GB
  • Currency GBP

Company Summary

DiagNodus Ltd (“DiagNodus”) is a biomedical technology start-up working in the field of early detection of colorectal cancer (CRC). DiagNodus is seeking to develop and commercialise Screen2C™. Screen2C™ is a developed method for population screening for CRC that addresses the need for a fully non-invasive, easy-to-use, self administering screening kit for individuals over the age of 50. 1.3 million new CRC cases were diagnosed worldwide in 2010,

Team

  • Default avatar
    Ben Bowmaker
    Mr

    Ben has worked in business for over 10 years working with start-up companies, advising science and technology entrepreneurs, raising finance and assembling balanced teams to develop and commercialise products. He has extensive experience as a consultant for large blue chip companies such as Merck KGaA and De La Rue on prototype design development and was CEO of Ver-tec Security Systems between 2002 and 2008.

  • Default avatar
    Alexandre Loktionov
    Dr

    Alex has 35 years research experience. He studied medicine in St Petersburg. He subsequently worked on molecular mechanisms of cancer at the WHO International Agency for Research on Cancer (IARC, France, 1989-1993) and then DKFZ, Germany, 1993-1995. In 1995 he joined the MRC Dunn Human Nutrition Unit in Cambridge (UK). In 2004, he became Scientific Dir. for Colonix, (now Origin Sciences) before founding DiagNodus Ltd. Dr Loktionov has authored ov

  • Default avatar
    Paul White
    Mr

    As Chairman to DiagNodus, Paul provides top level advisory support based on over 30 years of highly successful Public and Private sector leadership in healthcare delivery. 18 years as a CEO including 5 years as CEO of Barts Hospital and the London Hospitals Group, one of the UKs leading Academic Health Science Centres. Paul was also Director, Health Business, BT Global Services, 2008/9 and CEO of BT Health, London 2007/8.

  • Default avatar
    David Hamptom
    Dr

    As non-executive director to DiagNodus, David is an experienced leader in medical device innovation and new business development. David developed EEG analysis systems for neurology and psychiatry, later leading development teams in interpretive ECG systems and defribilation technologies and was also a Fellow at the Bakken Research Institute. He is a senior associate at Cambridge University, UK.

  • Default avatar
    Don Pinchetti
    Mr

    Don is an experienced international executive from the high-tech area with both large blue chip companies and start-up experience. He started his career at IBM and held senior positions in product development and manuacturing operations within the microelectronics division. Don became Director of Global Services at Leica in 2000 before being appointed Dir of Dev at Cavendish-Kinetics and then Vice President of Operations at Silicon Clocks.